CD8A and neoplasm: Our findings suggest that an “off-the-shelf” DC-targeted Ad3-based vaccine could benefit future immunotherapeutic approaches by increasing tumor-antigen specific CD8+ effector cells both in tumor-draining SLNs and systemically, that could next be unleashed in their proliferation and killing capacity by immune checkpoint blockade.